Autolus Therapeutics Plc. (AUTL), a company focused on T-cell therapies, announced on Wednesday that it has appointed Robert Dolski as chief financial officer with effect from August 7, to succeed Lucinda Crabtree.
As announced earlier, Crabtree will leave the company in August to pursue a new opportunity.
Dolski joins Autolus from Checkmate Pharmaceuticals Inc., where he served as CFO at the clinical-stage immuno-oncology biotech, acquired by Regeneron Pharmaceuticals Inc. in 2022.
Earlier, he had served as Vice President, Finance at Akcea Therapeutics.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.